The 6 most recent market catalysts affecting $ADMA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Neutral Rating on ADMA Biologics and Raises Price Target
Cantor Fitzgerald reaffirmed its Neutral rating on ADMA Biologics but raised its price target from $12 to $13, an 8.3% increase. This move, while not an upgrade in rating, signals …
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 75
ADMA Biologics shares are trading higher after the company announced the publication of a peer-reviewed article in Frontiers in Cardiovascular Medicine detailing new data from the company’s optimized, proprietary intravenous immune globulin manufacturing process.
This headline represents a significant positive catalyst for ADMA Biologics. The publication of peer-reviewed data validates the efficacy or efficiency of their optimized intraveno…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 85
ADMA Biologics Says Three-Lot Study Shows Updated IVIG Process Removes Clot-Linked Impurities, Raises Yield; No Clotting Events Reported Through July 2026
This news is a strong positive for ADMA Biologics. The successful removal of clot-linked impurities addresses a critical safety concern for IVIG products, potentially expanding the…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 55
ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est
ADMA Biologics filed an 8-K to affirm its fiscal year 2026 sales guidance, keeping it within the previously stated range of $530 million to $560 million. This is a routine update, …
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 92
ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate
ADMA Biologics announced its Q2 earnings, revealing a miss on both adjusted EPS and revenue compared to analyst consensus. The company reported $0.16 EPS against an estimated $0.17…
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 55
Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $17
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on ADMA Biologics, suggesting continued confidence in the company's long-term prospects. However, the simultaneous …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.